CashuVir Biotechnology to Announce Q4 Results and Corporate Update on February 26, 2025about 1 year ago
CashuVir Biotechnology's VIR-5818 Shows Promise in Cancer Treatment with Phase 1 Dataabout 1 year ago
CashuVir Biotechnology Showcases Innovative Treatments at 43rd J.P. Morgan Healthcare Conferenceabout 1 year ago
cnbc.comStocks making the biggest moves midday: IBM, AMD, Dillard's, Novo Nordisk & moreabout 16 hours ago
prnewswire.comAstellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer1 day ago
prnewswire.comCrown Racing Heads to VIR for Radical World Finals with a Four-Driver PRO 1340 Roster4 months ago